NEW YORK (GenomeWeb News) – Sequenom said this week that the California Technology Assessment Forum has completed an independent evaluation of the cell-free fetal DNA technology used in the Sequenom Center for Molecular Medicine's MaterniT21 Plus laboratory-developed test. According to the firm, CTAF recommended that the use of cell-free fetal DNA as a prenatal advanced screening test for fetal aneuploidy for Trisomy 21 and Trisomy 18 in high-risk women meets all five CTAF criteria for safety and efficacy and improvement in health outcomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.